Details
Stereochemistry | RACEMIC |
Molecular Formula | C22H30N2O |
Molecular Weight | 338.4864 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H]1CCC[C@@H](C)N1CCC[C@@](O)(C2=CC=CC=C2)C3=CC=CC=N3
InChI
InChIKey=APUDBKTWDCXQJA-XQBPLPMBSA-N
InChI=1S/C22H30N2O/c1-18-10-8-11-19(2)24(18)17-9-15-22(25,20-12-4-3-5-13-20)21-14-6-7-16-23-21/h3-7,12-14,16,18-19,25H,8-11,15,17H2,1-2H3/t18-,19+,22-/m1/s1
DescriptionCurator's Comment: description was created based on several sources, including:
DOI: 10.1111/j.1527-3466.1983.tb00446.x | https://www.ncbi.nlm.nih.gov/pubmed/3241147 | https://www.ncbi.nlm.nih.gov/pubmed/1381764
Curator's Comment: description was created based on several sources, including:
DOI: 10.1111/j.1527-3466.1983.tb00446.x | https://www.ncbi.nlm.nih.gov/pubmed/3241147 | https://www.ncbi.nlm.nih.gov/pubmed/1381764
Pirmenol is an antiarrhythmic agent, which exhibits effects on the fast action potential similar to other class 1 membrane active antiarrhythmic agents. Pirmenol depresses not only the fast Na+ channel, but also others, such as the slow Ca2+ and K+ channels. Pirmenol had sevenfold lower affinity for glandular-type muscarinic receptors (M3) than for cardiac-type muscarinic receptors (M2). This medicine regulates disturbed pulse by acting on the cardiac muscle. Usually, used for treatment of tachyarrhythmia (ventricular). The most commonly reported adverse reactions include constipation, discomfort in stomach, difficulty in urination (urinary retention), headache, insomnia, bitterness in the mouth, nausea, dry mouth and palpitation. Lidocaine, procainamide and quinidine a greater degree of arrhythmia conversion occurred when dosed 15 min after pirmenol than when these agents were dosed alone.
CNS Activity
Originator
Sources: https://www.google.com/patents/US4112103
Curator's Comment: http://www.chemdrug.com/article/8/3284/16419223.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Fast sodium-channels (rabbit) |
|||
Target ID: Slow potassium channels (rabbit) |
|||
Target ID: Slow calcium channels (rabbit) Sources: https://www.ncbi.nlm.nih.gov/pubmed/3241147 |
|||
Target ID: 1.00715344E8 Gene Symbol: Chrm2 |
|||
Target ID: 1.00379232E8 Gene Symbol: Chrm3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1381764 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PIMENOL Approved UseDrug is used for the treatment of tachyarrhythmia (ventricular). |
PubMed
Title | Date | PubMed |
---|---|---|
Pirmenol, a new antiarrhythmic agent: initial study of efficacy, safety and pharmacokinetics. | 1982 Feb |
|
Pharmacodynamics and pharmacokinetics of oral pirmenol. | 1987 Oct |
|
A patient responding to combined therapy with pirmenol and midodrine for refractory neurally mediated syncope complicated by prostatic hypertrophy. | 2004 Sep |
|
Progressive facilitation of antegrade conduction via an accessory pathway in a patient with Wolff-Parkinson-White syndrome and permanent atrial fibrillation. | 2005 Dec |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9600665
The IC50 of pirmenol for acetylcholine- and adenosine-induced current was about 1 and 8 microM in a single atrial myocytes
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47793
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL432103
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | |||
|
4685
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | |||
|
m8884
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB09925MIG
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | |||
|
DTXSID1043839
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | |||
|
68252-19-7
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | |||
|
VZ3B6ACV72
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | |||
|
C024318
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | |||
|
76962234
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | |||
|
2207
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | |||
|
C81434
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY | |||
|
100000081693
Created by
admin on Fri Dec 15 16:11:40 GMT 2023 , Edited by admin on Fri Dec 15 16:11:40 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)